Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 711 participants.
Also called NCT04986202
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 711 participants
- Sponsor
- Registry
-
NCT04986202 -
2020-005844-47
-
- Other papers using this trial's data
- Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, France, Hungary, Japan, Netherlands, Poland, Russia, Slovakia, Sweden, Taiwan, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT04986202. Randomized; triple masking; primary purpose treatment. Start 2021-06-30 (actual); primary completion 2024-03-27 (actual). Results posted on 2025-08-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
- Acronym
- ENDEAVOR
- Intervention (Drug)
- AZD4831
- Intervention (Other)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct04986202- Content hash
4a38a4fadd8523280ec36fcf20a03550375f4912160953809c418e1f2b443f71